Vericel (FRA:ATQP) Margin of Safety % (DCF Earnings Based): N/A (As of Jun. 25, 2026)


FRA:ATQP Vericel Corp FRA:ATQP
72 GF Score
Price €35.40
GF Value €46.10
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Vericel Margin of Safety % (DCF Earnings Based)?

Margin of Safety % (DCF Earnings Based) = (Intrinsic Value: DCF (Earnings Based) - Current Price) / Intrinsic Value: DCF (Earnings Based).

Note: Discounted Earnings model is only suitable for predictable companies (Business Predictability Rank higher than 1-Star). If the company's Predictability Rank is 1-Star or Not Rated, result may not be accurate due to the low predictability of business and the data will not be stored into our database.

Vericel's Predictability Rank is 1-Star. Thus, the DCF related results in the screener and portfolio will appear as zero and Margin of Safety % (DCF Earnings Based) is not calculated.

FRA:ATQP vs PVLA, TSHA, GENB: Margin of Safety % (DCF Earnings Based) Comparison

For the Biotechnology subindustry, Vericel's Margin of Safety % (DCF Earnings Based), along with its competitors' market caps and Margin of Safety % (DCF Earnings Based) data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Vericel Margin of Safety % (DCF Earnings Based) vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's Margin of Safety % (DCF Earnings Based) distribution charts can be found below:

* The bar in red indicates where Vericel's Margin of Safety % (DCF Earnings Based) falls into.


FRA:ATQP
72GF Score
Vericel Corp FRA:ATQP
Margin of Safety % (DCF Earnings Based) is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Vericel (FRA:ATQP) Overvalued in 2026?

Based on GuruFocus' analysis, Vericel stock appears to be undervalued. The current stock price of €35.40 is trading 23.2% below its estimated GF Value™ of €46.10. GuruFocus considers Vericel to be Modestly Undervalued.

Key valuation signals for FRA:ATQP:

  • Margin of Safety % (DCF Earnings Based): N/A
  • GF Value™: €46.10 vs. price of €35.40 (23.2% below fair value)
  • GF Score™: 72/100 with 5 warning signs

No single metric tells the full story. See the FRA:ATQP stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Vericel Business Description

Other Exchanges VCEL:USA
Address 64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated commercial-stage biopharmaceutical company and a provider of therapies for the sports medicine and severe burn care markets. It markets cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane); Epicel (cultured epidermal autografts); and NexoBrid. The Company operates its business in the U.S. in one reportable segment; the research, product development, manufacture, and distribution of cellular therapies and specialty biologics for use in the treatment of specific conditions.
72GF Score

Get the complete analysis for FRA:ATQP

Margin of Safety % (DCF Earnings Based) is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€35.40
Price
€46.10
GF Value